share_log

Ardelyx | DEF 14A: Definitive information statements

Ardelyx | DEF 14A: Definitive information statements

Ardelyx | DEF 14A：股東委託書決議
美股sec公告 ·  04/30 05:10
牛牛AI助理已提取核心訊息
Ardelyx, Inc., a biopharmaceutical company, announced the filing of its DEF 14A proxy statement with the U.S. Securities and Exchange Commission (SEC), detailing the upcoming annual meeting of stockholders scheduled for June 14, 2024. The meeting will be held entirely online, allowing stockholders to listen live and vote on key proposals. The agenda includes the election of two Class I directors, approval of amended equity and employee stock purchase plans, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2024. The proxy statement also outlines the company's corporate governance practices, director compensation, and equity compensation plans. Stockholders as of April 15, 2024, are eligible to vote at the meeting. The board recommends voting 'FOR' all proposals, including the election of director nominees, the approval of the equity incentive and employee stock purchase plans, the advisory approval of named executive officer compensation, and the ratification of the accounting firm.
Ardelyx, Inc., a biopharmaceutical company, announced the filing of its DEF 14A proxy statement with the U.S. Securities and Exchange Commission (SEC), detailing the upcoming annual meeting of stockholders scheduled for June 14, 2024. The meeting will be held entirely online, allowing stockholders to listen live and vote on key proposals. The agenda includes the election of two Class I directors, approval of amended equity and employee stock purchase plans, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2024. The proxy statement also outlines the company's corporate governance practices, director compensation, and equity compensation plans. Stockholders as of April 15, 2024, are eligible to vote at the meeting. The board recommends voting 'FOR' all proposals, including the election of director nominees, the approval of the equity incentive and employee stock purchase plans, the advisory approval of named executive officer compensation, and the ratification of the accounting firm.
生物製藥公司Ardelyx, Inc. 宣佈向美國證券交易委員會（SEC）提交了其DEF 14A委託聲明，詳細說明了定於2024年6月14日舉行的年度股東大會。會議將完全在線舉行，允許股東現場收聽關鍵提案並進行投票。該議程包括選舉兩名一級董事，批准經修訂的股權和員工股票購買計劃，關於高管薪酬的諮詢投票，以及批准安永會計師事務所作爲截至2024年12月31日的財政年度的獨立核數師。委託書還概述了公司的公司治理慣例、董事薪酬和股權薪酬計劃。截至2024年4月15日，股東有資格在會議上投票。董事會建議對所有提案投贊成票，包括董事候選人選舉、股權激勵和員工股票購買計劃的批准、指定執行官薪酬的諮詢批准以及會計師事務所的批准。
生物製藥公司Ardelyx, Inc. 宣佈向美國證券交易委員會（SEC）提交了其DEF 14A委託聲明，詳細說明了定於2024年6月14日舉行的年度股東大會。會議將完全在線舉行，允許股東現場收聽關鍵提案並進行投票。該議程包括選舉兩名一級董事，批准經修訂的股權和員工股票購買計劃，關於高管薪酬的諮詢投票，以及批准安永會計師事務所作爲截至2024年12月31日的財政年度的獨立核數師。委託書還概述了公司的公司治理慣例、董事薪酬和股權薪酬計劃。截至2024年4月15日，股東有資格在會議上投票。董事會建議對所有提案投贊成票，包括董事候選人選舉、股權激勵和員工股票購買計劃的批准、指定執行官薪酬的諮詢批准以及會計師事務所的批准。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。